UBT251
UBT251 Injection Phase II Study (Overweight or Obesity)
The United Bio-Technology (Hengqin) Co · Phase 2 · Completed · Enrollment 205
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| UBT251 Injection 2.0 mg | n/r | n/r | n/r | n/r |
| UBT251 Injection 4.0 mg(ID 0.5 mg) | n/r | n/r | n/r | n/r |
| UBT251 Injection 4.0 mg(ID 1.0 mg) | n/r | n/r | n/r | n/r |
| UBT251 Injection 6.0 mg | n/r | n/r | n/r | n/r |
Not shown
- UBT251 Injection 2.0 mg: endpoint not reported
- UBT251 Injection 4.0 mg(ID 0.5 mg): endpoint not reported
- UBT251 Injection 4.0 mg(ID 1.0 mg): endpoint not reported
- UBT251 Injection 6.0 mg: endpoint not reported